Prognostic factors of early recurrence after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Figure 1 Patient enrollment and study population flowchart. Eighty patients met the inclusion and exclusion criteria and were categorized into two groups: Group 1 included 39 patients with recurrence within 1 year, and Group 2 included 41 patients with recurrence after more than 1 year or no recurrence during the follow-up period. CC: Completeness of cytoreduction; CRS: Cytoreductive surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy.

Figure 2 Kaplan–Meier analysis of overall survival comparing patients in the progression-free survival < 1-year group and progression-free survival ≥ 1-year group. The favorable progression-free survival (PFS) group had a significantly longer overall survival compared to the unfavorable PFS group.